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Rani Samuel1, Azizah Attard2,3 and Marinos Kyriakopoulos1,3*Abstract
Background: The appropriateness of use of generic instead of brand-name medication remains unresolved and
controversial in several areas of medicine. Some evidence suggestive of variations in bioavailability and clinical
effectiveness between different formulations make policy decisions occasionally difficult. The use of generic
olanzapine is a widely acceptable practice on the basis of quality, safety and efficacy data and has been adopted in
several countries.
Case presentation: The case of a 14 year old boy with bipolar affective disorder, autism and intellectual disability
who had brand-name to generic olanzapine switch associated with rapid deterioration of his mental state is
described. This clinical change was not related to any physical illness or other medication adjustment and resolved
as rapidly when generic olanzapine was switched back to the brand-name formulation.
Conclusions: Caution should be exercised when policy for switching from brand-name to generic psychotropic
medications are made, especially when using medications off label, in extremes of age and in those patients with
co-morbid complicating factors such as intellectual disability.
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The appropriateness of substituting brand-name medica-
tion with generic medication policy remains unresolved
and controversial in several areas of medicine. In many
instances bioavailability and therapeutic efficacy vary be-
tween brand-name and generic drugs, and whether or
not bioequivalence reflects clinical equivalence is still
contentious [1,2]. One review highlights a few examples
of clinical difficulties when switching from brand-name
to generic preparations: plasma levels of phenytoin were
31% lower after a switch from a brand-name to a generic
product; several controlled studies of carbamazepine* Correspondence: marinos.kyriakopoulos@kcl.ac.uk
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reproduction in any medium, provided the orshowed a recurrence of convulsions after the shift to a
generic formulation and sudden recurrence of seizures
occurred when generic valproic acid was substituted for
the brand-name product [3]. Another review highlights
variations in clinical effectiveness, changes in trough
plasma levels and allergies to over 25 types of psycho-
tropic medications [4]. It has also been suggested that
medications acting on the CNS, may be more prone to
changes when switching from brand to generic com-
pared to other medication categories [4]. Many hypothe-
sise these responses to be related to differences in
bioavailability between the two formulations, and statis-
tically significant differences in pharmacokinetic vari-
ables and allergy to the inactive ingredient in favour of
brand-name versus generic [2-4]. Variations in bioavail-
ability in some patient groups could also be linked to
significant differences in the way a drug is metabolised
potentially affecting treatment clinical effectiveness [5].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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assumption of a decreased in drug costs. However, this
assumption may not always be correct, in Canada for ex-
ample Layton and Barbeau determined that switching pa-
tients from original to generic clozapine would lead to no
cost savings if it were accompanied by an 11.2% relapse
incidences caused by the change [6].
The use of generic olanzapine has been a widely ac-
ceptable practice. Araszkiewicz and colleagues highlight
the safety and welcomed the use of generic olanzapine
given the extensive research on relapse rates following
use of brand-name, generic or both preparations in Poland
where the generic preparation has been available since
2003 [7]. The US Food and Drug Administration (FDA)
approved the first generic formulation of olanzapine in
October 2011 [8]. Based on the review of the data on qual-
ity, safety and efficacy, the Medicine and Health care prod-
ucts Regulatory Agency (MHRA) also approved the use of
generic olanzapine in June 2011 in the United Kingdom.
To our knowledge, there is only one recent case report on
adverse effects associated with switching from one prepar-
ation of olanzapine to another. In this, Goldberg described
a case of akathisia following switching from brand-name
to generic preparation of olanzapine in a 33 year old
man with a diagnosis of bipolar affective disorder, which
resolved on reverting back to the brand-name prepar-
ation [9].
Case presentation
We present a case of a 14 year old boy with diagnoses of
bipolar affective disorder, current episode mixed (ICD-10
F31.6), childhood autism (ICD-10 F84.0) and moderate
mental retardation (ICD-10 F71). He had an 18-month
history of gradual deterioration in his behaviour which on
admission included aggression, periods of excitement in-
terspersed with crying and head-banging, reduced need
for sleep, and overactivity and was subsequently admitted
to our inpatient unit. He was observed to present with dis-
inhibition and at times displayed inappropriate behaviour
towards fellow female inpatients and staff members.
His drug history includes a trial of risperidone, up to
2 mg per day which was partially successful but was as-
sociated with akathisia; a three week trial of quetiapine
up to 200 mg daily was clinically ineffective and had to
be prematurely discontinued due to clinical deterior-
ation. Finally, brand-name olanzapine was added and ti-
trated to 7.5 mg daily. In addition sodium valproate was
titrated to 800 mg twice daily. This combination yielded
the best improvement, in terms of mental state and func-
tioning both at home and on the inpatient unit. At that
point, after a 3-week period of sustained improvement,
due to changes in our hospital budgeting pharmacy policy,
generic olanzapine was given to the boy for the first time
instead of the brand-preparation. This change was notapparent to the patient due to his neurodevelopmental
problems. A noticeable deterioration in his mental state
was observed within 2 days following the change to gen-
eric olanzapine. No other changes in medications were
made. Symptoms that re-emerged included increased agi-
tation, aggression, reduced sleep and disinhibition. This
was not associated with any physical health problems,
change in other medication or environmental factors.
The generic olanzapine was increased to 10 mg daily
with no positive effect on his mental state. Following
this, the change from brand-name to generic olanzapine
was hypothesised to account for the boy’s mental state
deterioration. The brand-name olanzapine was restarted
at 10 mg daily, with improvement in his mental state
within 1 – 2 days.
Discussion
We present a case of a 14 year boy with an acute clinical
deterioration within 48 hours when changed to generic
brand olanzapine followed by subsequent return to a previ-
ous stable mental state. Although Goldberg described an
emergence of a new side-effect [9] we are describing a de-
cline in clinical effectiveness. In both cases the effects sub-
sided on reverting from generic to brand-name olanzapine.
Most generic drugs are marketed after they have
passed the bioequivalence tests, set by standard licensing
agencies such as the FDA. The objective of a typical bio-
equivalence study is to demonstrate that the test (brand-
name) and reference (generic) products achieve a similar
pharmacokinetic profile in plasma, serum and/or urine.
Bioequivalence studies usually involve administration of
test and reference drug formulations to 18–36 normal
healthy subjects, but patients with a target disease may
also be used [10]. Most patients are aged between 18 to
55 years of age. Children are almost never subjects of
such studies.
Research in different branches of medicine raise vari-
ous views regarding the use of generic preparations. For
instance, Van der Meersch et al. [10], in their systematic
review highlight the poor reporting of bioequivalence
studies for FDA approved drugs. Wilner [11] in his sur-
vey of neurological observations of break through sei-
zures of stable patients, whose medication had recently
changed from brand-name to generic preparations, re-
iterate the need for careful monitoring of drugs with
narrow therapeutic index. Yim [12] in their stimulation
study of Area Under the Curve (AUC) of brand-name
and generic preparations has highlighted the potential
dangers of switching from one generic preparation to an-
other. Kesselheim et al. [13], on the other hand in their
systematic review of majority of randomized controlled
trials of cardiac drugs show that despite the proof of simi-
lar bioequivalence of brand name and generic drugs there
is reluctance and negativity amongst clinicians toward use
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highlight the medical and economic consequences on the
health care system when switching from brand-name to
generic preparations of oral warfarin.
Conclusions
In conclusion, our case study adds to the breadth of case
reports and knowledge that exists on this subject. It is
also accepted by the authors that in this time where drug
budgets and health care costs are at the forefront of pol-
icy committee members, there is indeed a need for the
production and continued use of generic psychotropic
medications. However, we believe caution should be
exercised, when policy for switching from brand-name
to generic psychotropic medications are made. This is
especially so when using psychotropic medications off
label, in extremes of age where medication metabolism
may be affected and in those patients with co-morbid
complicating factors such as intellectual disability.
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